ProMetic Life Sciences Inc. announced today that it closed a previously announced private placement of 29,600,000 subordinate voting shares at C$0.365 per share with JPMorgan and Third Point LLC. Proceeds from the private placement totaled C$10.8 million.
Market Wire
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
FDA Clears Sofregen’s Voice Augmenter
The device uses a proprietary single-use catheter delivery system.
Allergan, St. Regis Tribe Seek SCOTUS Review of Sovereign Immunity Case
The Patent Trial and Appeal Board ruled last year that Native American tribes cannot use sovereign immunity as a defense against inter partes reviews.
FDAnews Drug Daily Bulletin
PROMETIC CLOSES C$10.8 MILLION PRIVATE PLACEMENT
June 8, 2006
